Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus

References

1. ↵
   1. Al-Shaikh GK,
   2. Almussaed EM,
   3. Fayed AA,
   4. Khan FH,
   5. Syed SB,
   6. Al-Tamimi TN,
   7. et al.

   (2014) Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus vaccine. Saudi Med J 35:1223–1230.

   OpenUrl
2. ↵
   1. Forman D,
   2. de Martel C,
   3. Lacey CJ,
   4. Soerjomataram I,
   5. Lortet-Tieulent J,
   6. Bruni L,
   7. et al.

   (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Cervical cancer most common in Kingdom of Saudi Arabia

   The Saudi Gazette, Available from URL: http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentid=20141202226148. Updated: 2014 December 02.
4. ↵
   1. Konno R,
   2. Sagae S,
   3. Yoshikawa H,
   4. Basu PS,
   5. Hanley SJ,
   6. Tan JH,
   7. et al.

   (2010) Cervical Cancer Working Group report. Jpn J Clin Oncol 40(Suppl 1):i44–i50.

   OpenUrlCrossRefPubMed
5. ↵
   1. Paavonen J,
   2. Naud P,
   3. Salmerón J,
   4. Wheeler CM,
   5. Chow SN,
   6. Apter D,
   7. et al.

   (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   (2013) Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older-United States; 2013. MMWR Surveill Summ 62(Suppl 1):1–19.

   OpenUrlCrossRefPubMed
7. ↵
   1. Garland SM,
   2. Hernandez-Avila M,
   3. Wheeler CM,
   4. Perez G,
   5. Harper DM,
   6. Leodolter S,
   7. et al.

   (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   (2014) Saudi Cancer Registry. Cancer incidence report, Saudi Arabia 2010 (Ministry of Health, Saudi Cancer Registry, Riyadh (KSA)), pp 7–108.
9. ↵
   1. Forman D,
   2. de Martel C,
   3. Lacey CJ,
   4. Soerjomataram I,
   5. Lortet-Tieulent J,
   6. Bruni L,
   7. et al.

   (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. World Health Organization

    (2014) The Weekly Epidemiological Record (WER) (World Health Organization, Geneva (CH)) Available from: http://www.who.int/wer/2014/en.
11. ↵
    1. de Sanjose S,
    2. Quint WG,
    3. Alemany L,
    4. Geraets DT,
    5. Klaustermeier JE,
    6. Lloveras B,
    7. et al.

    (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–1056.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Macartney KK,
    2. Chiu C,
    3. Georgousakis M,
    4. Brotherton JM

    (2013) Safety of human papillomavirus vaccines: a review. Drug Saf 36:393–412.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Angelo MG,
    2. Zima J,
    3. Tavares Da Silva F,
    4. Baril L,
    5. Arellano F

    (2014) Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 23:456–465.

    OpenUrlCrossRefPubMed